| Chronic obstructive pulmonary disease(COPD) is an irreversible and heterogeneous lung disease with high morbidity and mortality.Clinical treatments often include bronchodilators and anti-inflammatory drugs,but the prognosis is poor and the side effects are significant.Chinese medicine compounds,with their unique syndrome differentiation system,flexible combinations,and safe and effective characteristics,have been used as a treatment option for COPD.These compounds can intervene in the disease through a “multi-component,multi-target,multi-pathway” approach.Research has shown that among the numerous pathways regulating COPD,the interleukin-17(IL-17) signaling pathway plays a major role in the occurrence and development of COPD.In this pathway,the adaptor protein nuclear factor-κB activator 1(Act1) forms a signal transduction complex with IL-17R,Act1,tumor necrosis factor receptor-associated factor 6(TRAF6),and IκB kinase(IKK),activating downstream nuclear factor-κB(NF-κB) and other signaling pathways.This specific regulatory mechanism can modulate inflammatory responses,oxidative stress responses,and airway remodeling,thereby intervening in COPD.Therefore,this study systematically elucidated and reviewed the mechanisms of classic Chinese medicine compounds and monomers in regulating the IL-17 signaling pathway in the treatment of COPD,aiming to provide valuable references for the precise prevention and treatment of COPD. |
